TKT and prostate carcinoma: To determine the therapeutic efficacy of the hON-522E-promoter–directed gene therapy in the treatment of CRPC human prostate cancer in vivo, we evaluated the antitumor effect of Ad-522E-TK combined with GCV in a PC3M subcutaneous xenograft model in nude mice.